Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0034065 (pulmonary embolism)
 14,979 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Co-Cr-W-Ni alloy (L605) with high tensile strength is used in coronary stents. The thickness of individual strut of the stent is reduced which can decrease the stent restenosis rate. However, about 10% Ni element content in L605 is found to cause allergic reactions and pulmonary embolism, similar to the traditional 316L stainless steel. In this study, a novel nickel-free cobalt-base alloy Co-20Cr-12Fe-18Mn-2Mo-4W-N (wt%) was designed and fabricated in order to efficiently avoid the potential hazards of Ni element. Fe and Mn, essential elements of human body, were added in the alloy to substitute part of Co element. In comparison to L605 alloy, the tensile strength of the new alloy was higher than 1000MPa while elongation was above 55%. The pitting potential of the new alloy was measured close to 1000mV, also higher than that of L605 alloy. CCK-8 test indicated that the cytotoxicity of the new alloy is grade 1, reflecting that Co-20Cr-12Fe-18Mn-2Mo-4W-N alloy has no cytotoxic effects. There was no significant difference in the apoptosis rates between Co-20Cr-12Fe-18Mn-2Mo-4W-N and L605 alloy. The newly developed cobalt-base alloy showed excellent mechanical, corrosion resistance and biological properties, which could make it a desirable material for future clinical investigations.
 ...
PMID:Design and characterization of a novel nickel-free cobalt-base alloy for intravascular stents. 2853 66

D-dimer is an important marker of different coagulation diseases, such as venous thromboembolism (including deep vein thrombosis and pulmonary embolism) and disseminated intravascular coagulation. Though it is frequently used in many clinical diagnostic situations, the D-dimer assays currently lack standardization due to its inherent heterogeneity which makes the antibody-based methods have different quantitative results and cutoffs to define an abnormal value. In this study, we report the first antibody-free D-dimer quantification method. In the method, a cross-linked peptide of fibrin D domain carboxyl terminal cross-linked by the factor XIIIa was used to represent the D-dimer. By using a filter-aided sample preparation and a nickel immobilized metal affinity chromatography enrichment strategy, the complexity of the plasma sample was significantly reduced, and the cross-linked peptide was enriched effectively for analysis with parallel reaction monitoring in mass spectrometry. The linear range of this method was 3.125-400 nmol/L which spans over two magnitudes. Recovery and reproducibility of the method were found to be good. To further demonstrate the performance of our method, D-dimer concentrations of 25 human plasma samples were analyzed, and the results had a good correlation between with the commercial D-dimer assay kit used in hospitals. This method was completely antibody-free and has the potential to promote the standardization of D-dimer analysis.
 ...
PMID:A Mass-Spectrometry-Based Antibody-Free Approach Enables the Quantification of D-Dimer in Plasma. 3251 45